Protein Formulation Development
At HTL Biosolutions, Inc., we offer both consulting and contract research services on protein characterizations, stability testings and formulation development. Our company founder, Dr. Tiansheng Li, has nearly 13 years of working experience at Amgen Inc. Before leaving Amgen Inc., Dr. Li held the position of Preclinical Director at the Department of Pharmaceutics and Drug Delivery, and he has successfully led the completion of a number of protein formulation projects for clinical trials and the CMC sections for IND and BLA filings. At the invitation of ACS, Dr. Li has also taught training courses on protein formulation development at ACS Prospective Conferences in the past few years.
Key formulation services
On site training course on protein formulation development
Formulation protocol design for any particular protein project
Analytical method development to analyze protein formulations
Protein-Delivery device compatibility study
Shelf-life study of protein formulation
Accelerated stability study
Pre-formulation screening study
At HTL Biosolutions, Inc., we offer services focused on pre-formulation screening studies inculding pH screening, buffer screening, excipient screening, surfactant screening and preservative screening studies. Our company founder and scientists have extensive experiences in designing appropriate screening studies to save you time and effort. Novel combinations of appropriate screening studies shall also add useful data for potential patent applications.
Protein formulation optimization
At HTL Biosolutions, Inc., we offer technical services to optimize formulation parameters such as pH, salt concentration, stabilizer concentration, surfactant concentration etc. The optimization of formulation parameters is essential to establish manufacturing specification parameters.
Device compatibility study
At HTL Biosolutions, Inc., we offer customized services related to product-device compatibility study such as pre-filled syringe, auto-injector and syringe pump studies. Protein therapeutics are normally susceptible to surface denaturation, and there are in-depth regulatory requirements on stability studies covering protein-device (primary container) compatibility. We offer services focused on protein stability design and analysis, in combination with delivery devices.